Poxel (STU:7PO) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


STU:7PO Poxel SA STU:7PO
37 GF Score
Price €0.20
GF Value €1.09
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Poxel Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Poxel's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:7PO vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Poxel's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poxel Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poxel's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Poxel's Margin of Safety % (DCF Earnings Based) falls into.


STU:7PO
37GF Score
Poxel SA STU:7PO
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Poxel (STU:7PO) Overvalued in 2026?

Based on GuruFocus' analysis, Poxel stock appears to be undervalued. The current stock price of €0.20 is trading 82.1% below its estimated GF Value™ of €1.09. GuruFocus considers Poxel to be Possible Value Trap.

Key valuation signals for STU:7PO:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €1.09 vs. price of €0.20 (82.1% below fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the STU:7PO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Poxel Business Description

Address 259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
37GF Score

Get the complete analysis for STU:7PO

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€1.09
GF Value